Latest ImmunityBio News & Updates

See the latest news and media coverage for ImmunityBio. We track all announcements, press releases, and industry mentions in real time, all in one place.

ImmunityBio

Biotechnology company developing immunotherapies for cancer and infectious diseases

immunitybio.com

Headquarters: San Diego, United States
Founded year: 2014
Company type: Public company
Number of employees: 600–1,000

Last updated Today

Latest news about ImmunityBio

In short: ImmunityBio achieved record revenues and secured FDA acceptance for an ANKTIVA label expansion while resolving advertising compliance issues.

Company announcements

June 1 ImmunityBio

ImmunityBio presents new data across lung and bladder cancers

The data includes Phase 3 trial results in advanced NSCLC and a comparative analysis in BCG-unresponsive NMIBC.

May 20 ImmunityBio

ImmunityBio announces FDA acceptance of sBLA for ANKTIVA plus BCG

The sBLA seeks to expand ANKTIVA's label to BCG-unresponsive NMIBC with papillary disease, with a PDUFA date of January 6, 2027.

May 19 ImmunityBio

ImmunityBio presents comparative effectiveness data for NAI+BCG at AUA 2026

The data show higher complete response rates and longer duration compared to nadofaragene and TAR-200, with fewer adverse events.

May 18 ImmunityBio

ImmunityBio announces U.S. patents for ANKTIVA plus BCG through 2035

The five patents cover methods, compositions, and kits for treating non-muscle invasive bladder cancer, reinforcing the company's commercial position.

Media coverage

July 3 Börse Global

ImmunityBio Stock: FDA Warning about Anktiva - Global Stock Market

ImmunityBio CEO fights back against FDA advertising allegations, while insiders prepare stock sales. Despite warning signals, the stock records a 375 percent annual gain.

June 30 Urology Times

FDA receives resubmitted sBLA for NAI plus BCG in papillary NMIBC | Urology Times

ImmunityBio has resubmitted an sBLA for the combination following an FDA request for updated efficacy data.

June 30 Yahoo Finance

IBRX Stock At 3-Month High: Retail Bulls Eye July Catalysts Around Anktiva Saudi Expansion, Q2 Sales

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or...

June 24 MSN

IBRX stock surges 12% on Russell 1000 inclusion hopes

IBRX's current market capitalization is around $9 billion, positioning the stock as a candidate for inclusion in the large-cap index. ・Potential addition to the Russell...

Never miss news about ImmunityBio

Track ImmunityBio and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.

ImmunityBio competitors & trending companies

Browse news for competitors to ImmunityBio and other trending companies.